The Manufacturers Life Insurance Company Sells 59,010 Shares of Novo Nordisk A/S (NYSE:NVO)

The Manufacturers Life Insurance Company lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 58.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,251 shares of the company's stock after selling 59,010 shares during the period. The Manufacturers Life Insurance Company's holdings in Novo Nordisk A/S were worth $3,634,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. M. Kulyk & Associates LLC grew its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after purchasing an additional 119 shares during the last quarter. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after buying an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC increased its holdings in Novo Nordisk A/S by 4.2% during the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after buying an additional 126 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Trading Up 1.4 %

Shares of Novo Nordisk A/S stock traded up $0.90 during mid-day trading on Friday, hitting $65.75. 13,058,660 shares of the stock were exchanged, compared to its average volume of 6,374,098. The stock has a market capitalization of $295.06 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $69.21 and a 200 day simple moving average of $86.23.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.